What the FDA labels say about taking them together
Cobicistat and colchicine
Cobicistat's FDA label of February 10, 2026 names colchicine in its contraindications section; the colchicine labels PlainMeds reads (4) do not name cobicistat. The cobicistat label: “Coadministration with colchicine is contraindicated in patients with renal and/or hepatic impairment due to potential for serious and/or life-threatening reactions. …”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited).
What does the cobicistat label say about colchicine?
Cobicistat label, contraindicationsAlpha 1-adrenoreceptor antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine Antimycobacterial: rifampin Antineoplastics: irinotecan These contraindications apply only to TYBOST coadministered with atazanavir Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products:
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: Anti-gout: colchicine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ colchicine; Clinical Comment: Coadministration with colchicine is contraindicated in patients with renal and/or hepatic impairment due to potential for serious and/or life-threatening reactions. Treatment of gout flares in adult patients – coadministration of colchicine: 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days. …
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the colchicine label say about cobicistat?
Colchicine's label (effective July 22, 2025) and its 3 other brand-application labels do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Colchicine | |
|---|---|---|
| Labeled for | HIV | Gout |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.122 per tablet 0.6 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once